What to Know About Psychedelic Therapies Cited by Trump
A recent executive order from President Donald Trump directs health regulators to accelerate reviews of psychedelic treatments and expand federal funding for related research, prompted in part by advocates for ibogaine. Most psychedelics remain Schedule I substances in the United States, yet several compounds - including psilocybin, MDMA, ibogaine …